STOCK TITAN
  1. Home
  2. News
  3. CVKD

Cadrenal Therapeutics Inc - CVKD STOCK NEWS

Welcome to our dedicated news page for Cadrenal Therapeutics (Ticker: CVKD), a resource for investors and traders seeking the latest updates and insights on Cadrenal Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cadrenal Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cadrenal Therapeutics's position in the market.

News
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024
Rhea-AI Summary
Cadrenal Therapeutics, Inc. (CVKD) to present tecarfarin, a novel anticoagulant, at Noble Capital Markets' Virtual Healthcare Equity Conference. The presentation includes a Q&A session and 1x1 meetings for investors. The webcast will be available on the company's website and Channelchek for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.34%
Tags
conferences
-
News
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts
Rhea-AI Summary
Cadrenal Therapeutics, Inc. (CVKD) receives FDA Orphan Drug Designation for tecarfarin, a novel anticoagulant for rare cardiovascular conditions, expanding treatment options and market exclusivity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.86%
Tags
clinical trial
-
News
Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update
Rhea-AI Summary
Cadrenal Therapeutics, Inc. (CVKD) provided a corporate update, expanding tecarfarin development to include new medical conditions, engaged in strategic partnerships, appointed a new COO, and reported Q4 2023 financials. Recent reports show positive equity research coverage and participation in key conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.81%
Tags
earnings
News
Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference
Rhea-AI Summary
Cadrenal Therapeutics, Inc. (CVKD) announces participation at THT 2024 to discuss tecarfarin, a novel oral anticoagulant for rare medical conditions. Tecarfarin aims to prevent heart attacks, strokes, and deaths due to blood clots. It has FDA designations for ESKD, AFib, and APS. Tecarfarin offers a different metabolism pathway than warfarin and has shown positive results in human trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
conferences
-
News
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial
Rhea-AI Summary
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) has appointed Jeff Cole as the Chief Operating Officer to oversee manufacturing, supply chain operations, intellectual property, commercialization strategies, and partnering activities for tecarfarin, a novel Vitamin K Antagonist for anticoagulation therapy. With over 25 years of experience in global pharmaceutical manufacturing and commercial operations, Mr. Cole's appointment is expected to support the company's tecarfarin clinical program and evaluate partnering opportunities. His previous roles at Valeant Pharmaceuticals International and Espero BioPharma demonstrate a strong track record in product development, supply, and commercial operations. The appointment reflects the company's focus on addressing unmet needs for patients with left ventricular assist devices (LVADs), antiphospholipid syndrome (APS), end-stage kidney disease (ESKD), and atrial fibrillation (AFib).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.47%
Tags
management clinical trial
-
News
Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions
Rhea-AI Summary
Cadrenal Therapeutics, Inc. announces the citation of a peer-reviewed article in the Journal of the American College of Cardiology highlighting the need for VKA-based anticoagulant therapy. The article emphasizes the limitations of DOACs in conditions such as mechanical heart valves, thrombotic APS, and AFib associated with ESKD. It also underscores the need for the advancement of tecarfarin development program to address critical gaps in anticoagulation therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
none
News
Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
Rhea-AI Summary
Cadrenal Therapeutics, Inc. (CVKD) announced that its Chief Medical Officer will participate in a fireside chat at the Lytham Partners 2024 Investor Select Conference. The company will also host one-on-one meetings with investors. The webcasted fireside chat is scheduled for February 1, 2024, and can be accessed online. Management will be participating in virtual one-on-one meetings throughout the event. Further information on the conference is available at the provided link.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.22%
Tags
conferences
-
News
Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference
Rhea-AI Summary
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) will present tecarfarin, a late-stage oral anticoagulant, at Biotech Showcase™ 2024 and the J.P. Morgan 42nd Annual Healthcare Conference. Tecarfarin targets orphan diseases, providing stable anticoagulation for patients with conditions like End-Stage Kidney Disease, Left Ventricular Assist Devices, and Antiphospholipid Syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
conferences
-
News
Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target
Rhea-AI Summary
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) has received an 'Outperform' rating and a price target of US$4.00 per share from Noble Capital Markets for its late-stage novel oral anticoagulant tecarfarin, designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with certain orphan diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.86%
Tags
none
News
Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization
Rhea-AI Summary
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) has engaged The Sage Group to explore strategic partnerships, co-development, and licensing agreements for tecarfarin, a novel oral and reversible anticoagulant. Tecarfarin addresses the need for stable anticoagulation in patients with certain orphan diseases, including ESKD with AFib, LVADs, and APS. The drug has shown promising results in clinical trials and has been granted orphan drug and fast-track designations by the FDA. Cadrenal estimates the combined addressable market opportunity to be in excess of US $2 billion per year in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
Stock CVKD logo
Cadrenal Therapeutics Inc

Nasdaq:CVKD

CVKD Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

CVKD Stock Data

6.61M
8.02M
46.72%
3.45%
0.26%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Ponte Vedra